Processing

Please wait...

Settings

Settings

Goto Application

1. WO2014168821 - VACCINE COMPOSITION AND METHOD OF USE

Publication Number WO/2014/168821
Publication Date 16.10.2014
International Application No. PCT/US2014/032938
International Filing Date 04.04.2014
IPC
A61K 39/39 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
39characterised by the immunostimulating additives, e.g. chemical adjuvants
CPC
A61K 2039/545
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
545characterised by the dose, timing or administration schedule
A61K 2039/55505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
555characterised by a specific combination antigen/adjuvant
55505Inorganic adjuvants
A61K 2039/55566
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
555characterised by a specific combination antigen/adjuvant
55511Organic adjuvants
55566Emulsions, e.g. Freund's adjuvant, MF59
A61K 2039/55572
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
555characterised by a specific combination antigen/adjuvant
55511Organic adjuvants
55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
A61K 31/7032
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
7032attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Applicants
  • MEDIMMUNE, LLC [US]/[US]
Inventors
  • LAMBERT, Stacie, Lynn
  • STILLMAN, Elizabeth, Ann
  • TANG, Roderick
  • WOO, Jennifer, Chui Ling
  • VAN NEST, Gary
Agents
  • TAN-AQUINO, Peilin
Priority Data
61/809,56308.04.2013US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) VACCINE COMPOSITION AND METHOD OF USE
(FR) COMPOSITION DE VACCIN ET SON PROCÉDÉ D'UTILISATION
Abstract
(EN)
Described herein is a vaccine composition and methods of use. In one embodiment, the vaccine composition includes RSV-F protein in combination with an adjuvant. In a more particular embodiment, the vaccine composition includes RSV soluble F protein in combination with a lipid toll-like receptor (TLR) agonist. In a more particular embodiment, the adjuvant comprises Glucopyraonsyl Lipid A (GLA). In a further embodiment, the adjuvant comprises GLA in a stable oil-in- water emulsion (GLA-SE).
(FR)
La présente invention concerne une composition de vaccin et ses procédés d'utilisation. Dans un mode de réalisation, la composition de vaccin comprend une protéine RSV-F en combinaison avec un adjuvant. Dans un mode de réalisation plus particulier, la composition de vaccin comprend une protéine F soluble de RSV en combinaison avec un agoniste lipidique du récepteur de type toll (TLR). Dans un mode de réalisation plus particulier, l'adjuvant comprend le glucopyranosyl lipide A (GLA). Dans un mode de réalisation supplémentaire, l'adjuvant comprend GLA dans une émulsion stable huile-dans-l'eau (GLA-SE).
Latest bibliographic data on file with the International Bureau